These researchers would be in Africa fighting ebola—but Trump cut their funding

As the world struggles to contain the rapidly growing Ebola outbreak in the Democratic Republic of the Congo’s Ituri Province, a vital network of research centers has been unable to help on the ground. The reason: The Trump administration slashed its funding last year, in part due to conspiracy theories about the origins of COVID-19.

Established in 2020 by the National Institutes of Health, the Centers for Research in Emerging Infectious Diseases (CREID) Network was conducting research into viruses that emerge from wildlife and spill over to people, including the family of viruses that Ebola belongs to. The network operated 10 sites around the world where these types of disease outbreaks are likely to occur, including in Central and East Africa. (The network was also researching hantavirus, a disease that saw a recent rare outbreak on a cruise ship.)

NIH provided CREID with approximately $82 million in funding over five years, and its funding was up for renewal in 2025. But last June, the centers received a stop-work order stating that their research had been deemed “unsafe for Americans and not a good use of taxpayer funding,” and that the agency’s priorities no longer supported the network.

“That reason is pretty rich, right? Because that was really the kind of pandemic preparedness research that we need to do,” says Kristian Andersen, an evolutionary virologist at Scripps Research in La Jolla, California, who led one of the two CREID centers in West Africa. Andersen was involved in developing diagnostics and conducted genomic sequencing of Ebola virus genomes during past outbreaks to learn how the virus was evolving and spreading. He doesn’t have NIH funding to do that kind of work now.

He says he is talking to colleagues in the DRC and reviewing data about the outbreak, but isn’t able to offer support with testing or sequencing. “We sit here in San Diego and see this unfold,” he says.

“The whole network would have mobilized,” says Robert Garry, a professor of microbiology and immunology at Tulane Medical School, who led the center with Andersen.